STOCK TITAN

Oramed (NASDAQ: ORMP) CEO uses 44,818 shares to cover RSU tax withholding

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ORAMED PHARMACEUTICALS INC. President and CEO Nadav Kidron reported a routine tax-related share disposition. On March 30, 2026, 44,818 shares of common stock were used to satisfy tax withholding obligations from the vesting of Restricted Stock Units at $3.31 per share. These shares were not sold in the open market but withheld to cover taxes. Following this, Kidron directly holds 3,422,243 common shares and indirectly holds 126,000 common shares through a wholly-owned corporation.

Positive

  • None.

Negative

  • None.
Insider KIDRON NADAV
Role President and CEO
Type Security Shares Price Value
Tax Withholding Common Stock 44,818 $3.31 $148K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 3,422,243 shares (Direct); Common Stock — 126,000 shares (Indirect, By wholly-owned corporation)
Footnotes (1)
  1. [object Object]
Tax-withholding shares 44,818 shares Common stock used to satisfy RSU tax obligations
RSU tax valuation price $3.31 per share Closing price on day before vesting used for tax withholding
Direct holdings after transaction 3,422,243 shares Common stock directly held by Nadav Kidron after withholding
Indirect holdings after transaction 126,000 shares Common stock held indirectly through a wholly-owned corporation
Restricted Stock Units financial
"vesting and settlement of Restricted Stock Units, which were valued at the closing price"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"used to satisfy tax withholding obligations attributable to the vesting and settlement"
wholly-owned corporation financial
"total_shares_following_transaction 126000.0000 ... nature_of_ownership By wholly-owned corporation"
common stock financial
"Represents shares of common stock, par value $0.012 per share ("Common Stock")"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KIDRON NADAV

(Last)(First)(Middle)
1185 AVENUE OF THE AMERICAS
THIRD FLOOR

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/30/2026F44,818(1)D$3.31(1)3,422,243D
Common Stock126,000IBy wholly-owned corporation
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share.
/s/ Nadav Kidron03/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ORMP CEO Nadav Kidron report on this Form 4?

Nadav Kidron reported that 44,818 ORMP common shares were used to cover tax withholding from vested Restricted Stock Units at $3.31 per share. This was a tax-withholding disposition rather than an open-market sale, tied directly to equity compensation vesting.

Were ORMP shares sold on the open market in this Form 4 filing?

No open-market sale occurred in this filing. The 44,818 ORMP shares were withheld by the issuer to satisfy Kidron’s tax obligations from RSU vesting, valued at the prior-day closing price of $3.31 per share, instead of being sold through the market.

How many ORMP shares does Nadav Kidron hold after the reported transactions?

After the tax-withholding disposition, Nadav Kidron directly holds 3,422,243 ORMP common shares. He also indirectly holds 126,000 additional common shares through a wholly-owned corporation, giving him substantial ongoing exposure to the company’s equity following this routine compensation-related event.

What price was used to value ORMP shares for the RSU tax withholding?

The RSU-related tax withholding used a valuation of $3.31 per ORMP share. This price reflects the closing price of Oramed Pharmaceuticals’ common stock on the trading day immediately before the vesting date, as specified in the Form 4 explanatory footnote.